Our CEO, Tuija Keinonen, will give a presentation titled 'Rokote Approach for Nasal Vaccination' at the World Vaccine Congress Europe in Barcelona on Tuesday, October 17th, at 12:05 PM.
We are delighted to have this opportunity to discuss intranasal vaccines and the development status of our vaccine. We are more than happy to engage in a chat about collaboration possibilities and vaccine development during the event.
The World Vaccine Congress Europe is the largest and most established European meeting on vaccine R&D. Join us there!
Link to the event: https://www.terrapinn.com/conference/world-vaccine-congress-europe/index.stm
Rokote Laboratories Finland Oy's intranasal coronavirus vaccine has transitioned from the product development phase to the production phase
Following the completion of the research and development phase for Rokote Laboratories Finland Oy's FINCoVac 2.1 coronavirus vaccine in early summer, the vaccine has advanced to the next stage in the production process at a designated contract manufacturer. This marks a significant milestone in the vaccine's development.
Multi-stage Production of the Drug Batch
Rokote Laboratories Finland Oy's drug (vaccine) is vector-based, utilizing a safe adenovirus as a carrier. Within the virus vector, the DNA sequence of the coronavirus spike protein has been cloned. The GMP-level production process of the virus vector vaccine began with the preparation of a large virus bank called the Master Viral Seed Stock (MVSS). The virus bank has already been prepared by Rokote Laboratories Finland Oy's contract manufacturer in Belgium. The MVSS virus bank has been divided into multiple sub-banks and is stored at -80°C to ensure long-term viability. The MVSS serves as the starting material to produce production-scale drug batches, and it can be used to produce several hundred drug batches.